For example, theasaponin E1 has demonstrated anti-inflammatory properties in the treatment of AD by inhibiting the NF-κB pathway in a dose-dependent manner, ultimately leading to a reduction in levels of inflammatory cytokines such as IL-1β, IL-6, and TNF-α [121]. This evidence concerns the gene IL6 and Alzheimer disease.